Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Nā hopena hoʻohiki o ka CD7 CAR-T Therapy i hui pū ʻia me ka lua o ka hoʻololi ʻana i nā maʻi T-ALL/LBL i hoʻihoʻi ʻia

2024-08-30

I ka ʻimi mau nei e hoʻomaikaʻi i nā koho lapaʻau no nā poʻe maʻi me ka relapsed T-cell acute lymphoblastic leukemia (T-ALL) a me ka lymphoblastic lymphoma (LBL), ua hōʻike ʻia kahi noiʻi hou e hāʻawi ana ka hui pū ʻana o ka lāʻau lapaʻau CD7 chimeric antigen receptor T-cell (CAR-T) me ka lua o ka allogeneic hematopoietic stem cell transplantation (HSCT) i nā hopena hoʻohiki. Ua hoʻomaka mua ʻia kēia ʻano hana hou ma ka Halemai ʻo Hebei Yanda Lu Daopei a me ka Halemai ʻo Beijing Lu Daopei, me ka laulima pū ʻana me Bioocus, a ua hōʻike ʻia nā ʻike ma ka 65th American Society of Hematology (ASH) Annual Meeting.

Ua kālele ke aʻo ʻana ma luna o 16 mau maʻi i hana mua ʻia ma HSCT a ua loaʻa iā lākou kahi relapse. Ua loaʻa i kēia mau maʻi ka lāʻau lapaʻau CD7 CAR-T, e alakaʻi ana i kahi hoʻokō kupaianaha 100% o ka hoʻokuʻu piha ʻana o MRD-negative i loko o ka iwi iwi. Eia kekahi, ua hōʻike pū ka lāʻau lapaʻau i ka pono i ka mālama ʻana i nā ʻeha extramedullary, me ka helu hoʻokuʻu piha ʻana o 75%.

8.31.jpg

 

Ma hope o ka lāʻau lapaʻau CD7 CAR-T, ua hana ʻia nā maʻi i ka lua o ka HSCT. ʻO ka helu ola holoʻokoʻa (OS) hoʻokahi makahiki he 58.5%, a ʻo ka helu ola leukemia-free (LFS) he 51.4%, e hōʻike ana i ka hiki o kēia hoʻolālā therapeutic i hui pū ʻia. Hōʻike nā hopena

ʻo ka lāʻau lapaʻau CD7 CAR-T, i ka wā e ukali ʻia ai e ka lua o ka HSCT, hiki ke lilo i koho lapaʻau kūpono no nā poʻe maʻi i pau i nā ala ʻē aʻe, e hāʻawi ana iā lākou i kahi manawa hou i ke kala ʻana no ka wā lōʻihi.

Hōʻike ka haʻawina i ka hiki o ka lāʻau lapaʻau CAR-T i ka hoʻololi ʻana i ke ʻano lapaʻau no T-ALL a me LBL, ʻoi aku hoʻi no nā poʻe maʻi i hoʻi hou ma hope o kahi hoʻoili mua. ʻO ka hoʻohui ʻana o nā pūnaewele CD7 CAR-T, e kuhikuhi ana i nā māka maʻi kanesa kikoʻī, me ka hoʻoili ʻana ma hope, e hōʻike ana i kahi hoʻolālā ikaika e hakakā ai i kēia mau maʻi kanesa ʻino.

Ke hoʻomau nei ʻo Bioocus, me ka hui pū ʻana me ka Halemai ʻo Lu Daopei, i ka ʻimi a me ka hoʻomaikaʻi ʻana i nā lāʻau lapaʻau CAR-T e hāʻawi i nā koho lapaʻau hou loa no nā maʻi hematologic malignancies. I ka holomua ʻana o ka noiʻi, ʻo ka manaʻolana e hoʻomaikaʻi hou aku i nā helu ola a me ke ʻano o ke ola no nā poʻe maʻi e kū nei i kēia mau maʻi paʻakikī.

Hōʻike kēia haʻawina i kahi ʻanuʻu koʻikoʻi i mua i ka mālama ʻana i ka T-ALL a me LBL i hoʻihoʻi ʻia, e hōʻike ana i ka hiki o nā ʻano lapaʻau hou i ka hāʻawi ʻana i nā hopena maikaʻi aʻe no nā poʻe maʻi ma ka honua holoʻokoʻa.